Capecitabine, Bevacizumab, and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study

C. Tebbutt, Niall; Wilson, Kate; Gebski, Val; M. Cummins, Michelle; Zannino, Diana; A. Van Hazel, Guy; A. Robinson, Bridget; Broad, A.; Ganju, Vinod; P. Ackland, Stephen; Forgeson, Garry; Cunningham, David; Saunders, Mark; R. Stockler, Martin; Chua, Yujo; Zalcberg, John; J. Simes, R.; Price, Timothy

doi:10.1200/jco.2009.27.7723

Public

Capecitabine, Bevacizumab, and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study

Published in Journal of Clinical Oncology • Jun 1, 2010

Authors:

Niall C. Tebbutt

Kate Wilson

Val Gebski

Abstract

PURPOSE: To determine whether adding bevacizumab, with or without mitomycin, to capecitabine monotherapy improves progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC) in an open-label, three-arm randomized trial. PATIENTS AND METHODS: Overall, 471 patients in Australi...

Subject

Capecitabine

Medicine

Bevacizumab

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!